Anthem Biosciences Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Anthem Biosciences Ltd is ₹ 782 as of 11 Jun 10:48 . The P/E Ratio of Anthem Biosciences Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 37.3 on March 2026 . This represents a CAGR of -9.55% over 6 years The Market Cap of Anthem Biosciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 38682 crore on March 2026 . This represents a CAGR of 7.98% over 6 years The revenue of Anthem Biosciences Ltd for the Mar '26 is ₹ 663.14 crore as compare to the Dec '25 revenue of ₹ 456.68 crore. This represent the growth of 45.21% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The ebitda of Anthem Biosciences Ltd for the Mar '26 is ₹ 319.41 crore as compare to the Dec '25 ebitda of ₹ 165.36 crore. This represent the growth of 93.16% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The net profit of Anthem Biosciences Ltd changed from ₹ 82.38 crore to ₹ 189.76 crore over 8 quarters. This represents a CAGR of 51.77% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The Dividend Payout of Anthem Biosciences Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 95.44 % on March 2026 . This represents a CAGR of -6.42% over 6 years .

About Anthem Biosciences Ltd

Anthem Biosciences Limited was originally incorporated as 'Anthem Biosciences Private Limited', dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to 'Anthem Biosciences Limited' and a Certificate of Incorporation was issued by RoC on December 10, 2024. The Company has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries. The Company started operations at Unit I and set up a Custom Synthesis Plant with a capacity of 6 KL in year 2007.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Anthem Biosciences Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Anthem Biosciences Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Anthem Biosciences Ltd is 44,413 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 35,925 Cr

What are the key factors driving the stock performance of Anthem Biosciences Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Anthem Biosciences Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Anthem Biosciences Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of June 14, 2026, the Anthem Biosciences Ltd stock price is INR ₹788.6. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2120.7.

How do dividend payouts of Anthem Biosciences Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Anthem Biosciences Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.